Dynamics of chronic myeloid leukaemia
暂无分享,去创建一个
Martin A. Nowak | Yoh Iwasa | Franziska Michor | Susan Branford | Timothy P. Hughes | M. Nowak | Y. Iwasa | C. Sawyers | F. Michor | N. Shah | T. Hughes | Charles L. Sawyers | Neil P. Shah | S. Branford | T. Hughes
[1] J. Melo,et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.
[2] H. Kantarjian,et al. Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.
[3] John H. Jopson,et al. A REPORT OF TWO CASES , 1902 .
[4] Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.
[5] Branford,et al. Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.
[6] T. Kunkel,et al. DNA replication fidelity. , 1992, The Journal of biological chemistry.
[7] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[8] Helen Moore,et al. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. , 2004, Journal of theoretical biology.
[9] M. Slovak,et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.
[10] J. Goldman,et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. , 1996, Blood.
[11] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[12] A. Elmaagacli,et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method , 2001, British journal of haematology.
[13] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[14] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[15] C. Preudhomme,et al. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. , 2003, The New England journal of medicine.
[16] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[17] P. Browett,et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase , 2003, Leukemia.
[18] M. Slovak,et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. , 2002, Blood.
[19] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[20] M C Mackey,et al. Periodic chronic myelogenous leukaemia: spectral analysis of blood cell counts and aetiological implications , 1999, British journal of haematology.
[21] C. Sawyers,et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. , 2005, Blood.
[22] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[23] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[24] I. Weissman,et al. The biology of hematopoietic stem cells. , 1995, Annual review of cell and developmental biology.
[25] Claude Preudhomme,et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.
[26] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[27] Yoshiya Tanaka,et al. Imatinib mesylate‐sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases , 2004, American journal of hematology.
[28] I. Weissman,et al. Purification and characterization of mouse hematopoietic stem cells. , 1988, Science.
[29] AC Eaves,et al. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia , 2002, Leukemia.
[30] R. Herrmann,et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. , 2004, Blood.
[31] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.
[32] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[33] A. Reiter,et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR , 1999, Leukemia.
[34] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[35] B. Zehnbauer,et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. , 1993, Blood.
[36] H. Kantarjian,et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] A. Fokas,et al. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. , 1991, Cancer research.
[38] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.